Thurston, Springer, Miller, Herd & Titak, Inc. Vertex Pharmaceuticals Inc Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $283 Million
- Q2 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 921 shares of VRTX stock, worth $447,596. This represents 0.15% of its overall portfolio holdings.
Number of Shares
921Holding current value
$447,596% of portfolio
0.15%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,625Shares Held
222MCall Options Held
1.35MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA25.6MShares$12.4 Billion1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA22.7MShares$11 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY22MShares$10.7 Billion0.22% of portfolio
-
State Street Corp Boston, MA12MShares$5.84 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY7.1MShares$3.45 Billion1.08% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $125B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...